Author (year) | Study description | Sample size | Time point | Criterion variable | MDA subgroup | Score |
Cross-sectional studies | Mean (SD) | |||||
Queiro et al (2017)25 | Cross-sectional observational study | 277 | — | PsAID total score* | MDA | 3.3 (3.1) |
Non-MDA | 7.1 (5.2) | |||||
P value | <0.001 | |||||
Longitudinal studies | Change from baseline | |||||
Mease et al (2017a)31 | Post hoc analysis of RCT to validate MDA criteria and HRQoL outcomes | 135 | Week 24 | SF-36 PCS | MDA | 13.3 |
Non-MDA | 3.5 | |||||
P value | <0.001 | |||||
SF-36 MCS | MDA | 5.0 | ||||
Non-MDA | 0.3 | |||||
P value | <0.01 | |||||
DLQI total | MDA | −5.8 | ||||
Non-MDA | −2.8 | |||||
P value | 0.01 | |||||
FACIT Fatigue | MDA | 8.6 | ||||
Non-MDA | 1.3 | |||||
P value | 0.001 | |||||
Coates et al (2016)30 | Post hoc analysis of RCT to validate MDA criteria and HRQoL outcomes | 397 | Week 24 | SF-36 PCS | MDA | 9.0 |
Non-MDA | 4.6 | |||||
P value | <0.001 | |||||
SF-36 MCS | MDA | 6.9 | ||||
Non-MDA | 4.1 | |||||
P value | <0.01 | |||||
DLQI | MDA | −9.9 | ||||
Non-MDA | −7.5 | |||||
P value | <0.01 | |||||
FACIT fatigue | MDA | 9.0 | ||||
Non-MDA | 4.9 | |||||
P value | <0.001 | |||||
PsA QoL | MDA | −5.2 | ||||
Non-MDA | −3.3 | |||||
P value | <0.001 | |||||
Week 52 | SF-36 PCS | MDA | 9.9 | |||
Non-MDA | 4.6 | |||||
P value | <0.001 | |||||
SF-36 MCS | MDA | 6.8 | ||||
Non-MDA | 4.4 | |||||
P value | <0.01 | |||||
DLQI | MDA | −10.7 | ||||
Non-MDA | −8.5 | |||||
P value | <0.01 | |||||
FACIT fatigue | MDA | 9.5 | ||||
Non-MDA | 5.4 | |||||
P value | <0.001 | |||||
PsA QoL | MDA | −5.7 | ||||
Non-MDA | −3.4 | |||||
P value | <0.001 |
*PsAID total score ranges from 0 (best health status) to 10 (worst health status).
DLQI, Dermatology Life Quality Index; FACIT, Functional Assessment of Chronic Illness Therapy; HRQoL, health-related quality of life;MCS, Mental Component Score; MDA, minimal disease activity; Non-MDA, patients not achieving MDA;PCS, Physical Component Score; PROs, patient-reported outcomes; PsAID, Psoriatic Arthritis Impact of Disease; PsA QoL, psoriatic arthritis quality of life; RCT, randomised controlled trial; SF-36, Short Form 36 Health Survey.